By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

Lucid Diagnostics Inc.  ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. , today announced that Highmark Blue Cross Blue ...

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

Vivani Medical, Inc. ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful administration of its ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

The decision is significant, as "it sets out principles whose scope exceeds the issue of the moratorium, affirming the unconstitutionality of regional regulations that conflict with the ...

The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported ...

The company wants to create two focused companies dedicated to driving current and future value in their respective ...

Crypto Bitwise Launches ETF Tracking Firms With Over 1,000 Bitcoin Melania Trump’s Official Memecoin, Worth Over $13 Billion ...

Vivani Medical (NASDAQ:VANI) said on Wednesday that it intends to divest its Cortigent unit, which builds neurostimulation ...